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summary, dietary sugar-induced increases of circulating 
ANGPTL3 concentrations after metabolic dysregulation cor-
related positively with leptin levels, HOMA-IR, and dyslipid-
emia.  Targeting ANGPTL3 expression with RNAi inhibited 
dyslipidemia by lowering plasma TGs, VLDL-C, APOC3, and 
APOE levels in rhesus macaques.—Butler, A. A., J. L. 
Graham, K. L. Stanhope, S. Wong, S. King, A. A. Bremer, R. 
M. Krauss, J. Hamilton, and P. J. Havel. Role of angiopoietin-
like protein 3 in sugar-induced dyslipidemia in rhesus ma-
caques: suppression by fish oil or RNAi. J. Lipid Res. 2020. 
61: 376–386.
Supplementary key words  triglycerides • insulin resistance • apolipo-
proteins • lipoproteins • inflammation • C-reactive protein • nonhuman 
primate • metabolic disorders • RNA interference
Elevated circulating lipids and lipoproteins are the major 
known modifiable risk factors for CVD, the leading cause 
of death in the United States (1–4). Severe hypertriglyceride-
mia  (e.g.,  >800 mg/dl)  also  increases  the  risk  for  acute 
pancreatitis, which can be life-threatening (5). The preva-
lence of hyperlipidemias increases with obesity and aging, 
although less common genetic disorders can also lead 





Abstract Angiopoietin-like protein 3 (ANGPTL3) inhibits 
lipid clearance and is a promising target for managing car-
diovascular disease. Here we investigated the effects of a 
high-sugar (high-fructose) diet on circulating ANGPTL3 
concentrations in rhesus macaques. Plasma ANGPTL3 con-
centrations increased 30% to 40% after 1 and 3 months of 
a high-fructose diet (both P < 0.001 vs. baseline). During 
fructose-induced metabolic dysregulation, plasma ANGPTL3 
concentrations were positively correlated with circulating in-
dices of insulin resistance [assessed with fasting insulin and 
the homeostatic model assessment of insulin resistance 
(HOMA-IR)], hypertriglyceridemia, adiposity (assessed as 
leptin), and systemic inflammation [C-reactive peptide (CRP)] 
and negatively correlated with plasma levels of the insulin-
sensitizing hormone adropin. Multiple regression analyses 
identified a strong association between circulating APOC3 
and ANGPTL3 concentrations. Higher baseline plasma lev-
els of both ANGPTL3 and APOC3 were associated with an 
increased risk for fructose-induced insulin resistance. Fish 
oil previously shown to prevent insulin resistance and hy-
pertriglyceridemia in this model prevented increases of 
ANGPTL3 without affecting systemic inflammation (increased 
plasma CRP and interleukin-6 concentrations). ANGPTL3 
RNAi lowered plasma concentrations of ANGPTL3, triglyc-
erides (TGs), VLDL-C, APOC3, and APOE. These decreases 
were consistent with a reduced risk of atherosclerosis. In 
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Abbreviations:  ANGPTL3,  angiopoietin-like  protein  3;  BW,  body 
weight at baseline; HFCS, high-fructose corn syrup; HOMA-IR, homeo-
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Angiopoietin-like  protein  3  (ANGPTL3)  is  a  secretory 
protein expressed in the liver (a “hepatokine”) and is con-
sidered  a  promising  lead  target  in  the  development  of 
lipid-lowering therapies (7). ANGPTL3 belongs to a family 
of  secretory  proteins  (ANGPTL3,  ANGPTL4,  and  ANG-
PTL8) that affect the clearance of circulating lipids by 
regulating  endothelial  lipase  and  lipoprotein  lipase  (8). 






ANGPTL3 gene variants associate with lower plasma levels 
of LDL-C and TGs and a lower risk of CVD (13–19). More-
over, small trials using antisense or monoclonal antibodies 










tion (24). Loss-of-function APOC3 gene variants associate 
with  significant  (40%)  reductions  in  CVD  risk  and 
plasma concentrations of TGs and LDL-C (6–9). Preclinical 













bolic  syndrome  (insulin  resistance,  hypertriglyceridemia, 
and increased APOC3) (28–30). Using this model, we re-
cently reported  that an RNAi construct  targeting hepatic 
APOC3  expression  reduces  plasma  TG  concentrations 












model  assessment of  insulin  resistance  (HOMA-IR)]  and 
dyslipidemia have previously been reported (28–31). These 
studies reported rapid gains in body weight, fasting hyper-



















Agriculture  Animal  Welfare  Act  and  the  National  Institutes  of 
















approximately  30%  of  their  daily  caloric  intake  from  fructose. 
Body weight measurements and fasting blood samples were col-
lected after 1 and 3 months of fructose consumption.
Ten additional  adult male  fructose-fed  rhesus monkeys were 
supplemented  with  4  g/day  whole  fish  oil  (Jedwards  Interna-
tional,  Inc.,  Braintree, MA)  for  6 months.  These  animals  were 
compared with a subset of nine animals from the group of 59 ani-
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4 mg/kg) was  administered  in  four  animals  via  subcutaneous 
injection on day 0 and day 29 (n = 4). Two additional animals 
received vehicle injections.
ARO-ANGPTL3  is  a  synthetic  double-stranded  (both  strands 
contain  21  nucleotides)  hepatocyte-targeted  N-acetylgalactos-
amine-conjugated  RNAi  molecule.  The  N-acetylgalactosamine 
moiety targets the RNAi into hepatocytes by acting as a ligand for 
the highly expressed hepatocyte-specific asialoglycoprotein recep-
tor. The RNAi construct was designed to silence ANGPTL3 mRNA 






Plasma glucose concentrations were measured using a glucose 
analyzer (YSI Life Sciences, Yellow Springs, OH). Plasma adipo-






by  subtracting HDL-C  and  LDL-C  from TC.  Plasma  ANGPTL3 
concentrations were measured using ELISA (DANL30; R&D Sys-
tems, Minneapolis, MN)  for human ANGPTL3  that  cross-reacts 












(33.50–42.39  nm),  and  small  (29.60–33.49  nm);  IDL:  large 
(25.00–29.59 nm) and small (23.33–24.99 nm); LDL: large (22.0–
23.32 nm), medium (21.41–21.99 nm), small (20.82–21.40 nm), 





analyses  (repeated-measures  ANCOVA,  multiple  linear  regres-
sion,  calculation  of  correlation  coefficients)  using  log-trans-
formed  data  were  performed  using  SPSS  Statistics  version  24 
(IBM, Armonk, NY).
Correlations  between  plasma  ANGPTL3  concentrations  with 
indices of glucose metabolism, lipid metabolism, and inflammation 
in the larger fructose consumption study (n = 59) were assessed by 
calculating  correlation  coefficients,  performing  regression,  or 
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High baseline plasma ANGPTL3 and APOC3 levels 
correlate with increases of HOMA-IR
Multiple linear regression analyses identified a strong re-
lationship between plasma ANGPTL3 and APOC3 concen-
trations  (supplemental  Table  S3, Fig.  1B).  Revising  the 
modeling equation to identify variables predicting plasma 
APOC3  concentrations  identified  ANGPTL3  levels  as  a 





pose  circulating  lipids  to  accumulation  during  fructose 
consumption.  These  hypotheses  were  assessed  in  a  pro-




Fig. 1.  Increased plasma ANGPTL3  concentrations 
during  fructose  consumption  and  correlations  be-
tween plasma ANGPTL3 and APOC3 concentrations. 
A:  Plasma ANGPTL3  concentrations  at  baseline  and 
after 1 or 3 months of dietary supplementation with a 
fructose-containing  beverage  (300  kcal/d).  ***P < 
0.001  versus  baseline.  B:  Scatterplots  showing  actual 
values  of  plasma  ANGPTL3  (x-axes)  and  APOC3  
(y-axes)  concentrations  at  baseline  and  during  fruc-
tose consumption. Significantly positively correlations 
are evident at all time points.





 Baseline 67.5 ± 3.9 56.2 ± 4.0 57.8 ± 3.9 Diet × tertile, P < 0.001
  3 months 63.3 ± 4.2 70.7 ± 4.3 96.5 ± 4.2
  4.3 ± 1.8*** 14.5 ± 1.9*** 38.8 ± 1.8*** ***P < 0.001 between all tertiles
Age (y) 11.7 ± 2.2 (7.8–16.2) 12.6 ± 3.1 (6.4–16.9) 11.6 ± 3.2 (6.4–17.8)
Body weight (kg)
 Baseline 16.3 ± 0.5 15.6 ± 0.5 15.8 ± 0.5 Diet, P < 0.005
  3 months 18.1 ± 0.5 17.1 ± 0.5 17.2 ± 0.5
  +1.9 ± 0.2 +1.5 ± 0.2 +1.4 ± 0.2
HOMA-IR
 Baseline 11.2 ± 2.5 16.1 ± 2.6 12.4 ± 2.5
  3 months 15.0 ± 9.5 25.0 ± 10.0 36.6 ± 9.7
  +3.8 ± 9.5 +9.0 ± 9.7 +23.2 ± 9.4
Leptin (ng/ml)
 Baseline 18.3 ± 2.5 18.7 ± 2.5 22.2 ± 2.4 Diet, P = 0.001
  3 months 21.2 ± 2.6 23.7 ± 2.7 29.3 ± 2.6*
  2.9 ± 1.3 5.0 ± 1.3 7.1 ± 1.3* *P < 0.05 vs. 1st tertile
Adiponectin (mg/dl)
 Baseline 8.1 ± 1.7 10.0 ± 1.8 9.9 ± 1.7 Diet, P = 0.001
  3 months 5.6 ± 1.0 7.2 ± 1.0 5.7 ± 1.0 Diet × BW, P = 0.001
  2.4 ± 0.9 2.9 ± 0.9 4.2 ± 0.9 Tertile, P = 0.07
CRP (mg/l)
 Baseline 1.8 ± 0.3 1.9 ± 0.3 1.8 ± 0.3 Diet, P = 0.058
  3 months 2.7 ± 0.4 3.5 ± 0.3 3.6 ± 0.3 Diet × tertile, P < 0.01
  0.9 ± 0.3 1.6 ± 0.3 1.8 ± 0.3* *P < 0.05 vs. 1st tertile
TGs (mg/dl)
 Baseline 71 ± 8 92 ± 8 87 ± 8
  3 months 140 ± 37 170 ± 38 245 ± 37
  69 ± 32 78 ± 33 159 ± 32 Tertile, P = 0.11
LDL-C (mg/dl)
 Baseline 66 ± 4 69 ± 4 64 ± 4
  3 months 72 ± 5 68 ± 5 66 ± 5
  6 ± 3 1 ± 3 2 ± 3
HDL-C (mg/dl)
 Baseline 66 ± 4 60 ± 4 62 ± 4
  3 months 68 ± 4 60 ± 4 54 ± 4




variables;  age, BW,  and BW (3 months) were used  as  covariates  for blood  chemistries. Asterisks  refer  to  significance determined by post hoc 
comparisons between tertiles.
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concentrations of ANGPTL3 and APOC3 differ by orders 
of magnitude  (ng/ml  vs. mg/dl),  log-transformed data 
were converted to z  scores  (SD  from  the  mean).  Age, 
body weight, and weight gain were controlled for in the 
analysis.
For baseline [APOC3]z there was a strong inverse corre-
lation with HDL-C (r = 0.53, P < 0.001) and less robust 
but still significant positive correlations with insulin and 
HOMA-IR (r = 0.29 and 0.28, P < 0.05). Similar associa-
tions  were  observed  for  [ANGPTL3]z  +  [APOC3]z  (for 
HDL-C, r = 0.38 and P < 0.005; for insulin, r = 0.30 and 
P < 0.05; and for HOMA-IR, r = 0.29 and P < 0.05). How-




+  [APOC3]z.  Both  variables  contributed  equally  to  in-
creases  of  [ANGPTL3]z  +  [APOC3]z  (supplemental  Fig. 
S3). While both baseline [APOC3]z or [ANGPTL3]z cor-





differences  for  TG  or  LDL-C  when  baseline  [APOC3]z, 
[ANGPTL3]z,  or  [ANGPTL3]z +  [APOC3]z tertiles were 
used as the fixed variable (Fig. 2C, D).
Low plasma ANGPTL3 levels are associated with higher 
plasma adropin concentrations
Plasma  concentrations  of  adropin,  a  secreted  peptide 
with insulin-sensitizing actions in skeletal muscle and liver 
in mouse models  (35–42), were  inversely  correlated with 
plasma ANGPTL3 concentrations after 3 months of  fruc-





Dietary fish oil prevents fructose-induced increases of 
plasma ANGPTL3
The  effects  of  fish  oil  supplementation  in  preventing 
fructose-induced dyslipidemia and increasing fasting insu-
lin  and  HOMA-IR  have  previously  been  reported  (29). 
Here we  report new  results  on  the  effects  of  fish oil  on 
fructose-induced changes of ANGPTL3 and CRP concen-
trations. There was  a  significant  effect of  time and high-
fructose  diet  on  plasma  concentrations  of  ANGPTL3 
(effect of time on diet in repeated-measures ANOVA: P < 
0.01) (Fig. 4A), APOC3 (P = 0.001) (Fig. 4B), and CRP  




We previously  reported  that  supplementing  the  fruc-
tose diet with fish oil attenuates fructose-induced hyperin-
sulinemia  and  hypertriglyceridemia  (29).  The  effects  of 
fish  oil  in  protecting  against  the  development  of  insulin 
resistance and dyslipidemia in this model thus appear to be 
independent of the attenuation of systemic inflammatory 











RNAi suppression of ANGPTL3 improves dyslipidemia 
induced by high-sugar diet
We  next  determined  whether  suppressing  ANGPTL3 




macaques  with  RNAi  targeting  the  Angptl3  gene  (ARO-
ANGPTL3) resulted  in a marked (>90%) reduction of 
plasma ANGPTL3 concentrations (Fig. 5A).
The  HFCS  diet  rapidly  induced  hypertriglyceridemia 
(Fig. 5). A comparison of  the mean of  the  last 3 days of 
measurements with baseline levels (days 0–8) indicated the 
effect of ARO-ANGPTL3 was highly significant (from 84 to 
6  ng/ml; P  <  0.01).  ARO-ANGPTL3  treatment markedly 
reduced  fasting  plasma  TG  concentrations  by  approxi-


























Although  there  was  a  trend  for  treatment  with  ARO-
ANGPTL3  to  attenuate  the  insulin  resistance  as  assessed 
with an intravenous glucose tolerance test, this did not 
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Fig. 2.  A combination of high baseline plasma concentrations of 
both APOC3 and ANGPTL3 correlates with the effects of fructose 
on  HOMA-IR  and  HDL-C.  Bar  graphs  show  estimated  marginal 
means and SEMs for changes () after 3 months of fructose con-
sumption.  Animals  are  grouped  into  tertiles  ranked  low  (1st)  to 
high  (3rd)  by  baseline  values  for  [APOC3]z  +  [ANGPTL3]z, 
[APOC3]z, or [ANGPTL3]z, where z is defined as the SD from the 
mean. The y-axes are changes in log-transformed values (HOMA-IR, 
HDL-C, TGs,  LDL-C).  Individual  unadjusted data  points  are  also 
shown  (gray  circles). A: Changes  in HOMA-IR after  3 months of 
fructose. A  significant effect of  tertile was observed only between 
[APOC3]z + [ANGPTL3]z tertiles (P < 0.005). Increases in HOMA-IR 






versus  2nd  and 3rd  tertiles. Declining HDL-C  concentrations  are 
more  frequently  observed  in  animals with high baseline  levels  of 





achieve  statistical  significance  (P  =  0.09)  (supplemental 
Fig. S4).
DISCUSSION





markers  of  systemic  inflammation  (CRP)  and  adiposity  
(leptin). The responses of ANGPTL3 to a high-sugar diet 
are significantly correlated with changes in the plasma lipid 
profile  (increases  of TGs  and  lowering  of HDL-C  levels) 
that predispose humans to CVD. This study defines for  
the first time significant positive relationships between cir-




















component  of HDL-C  and  also  correlated  inversely  with 
ANGPTL3  levels.  The  inverse  relationships  between 




leptin receptor mutations or with streptozotocin- 
induced  diabetes  indicate  increased  ANGPTL3  mRNA 
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linemia  and  elevated  plasma ANGPTL3  concentration 




















Previous reports have suggested that certain gene vari-
ants  that  lower TG  concentrations  and  reduce CVD  risk 
can also influence the risk of type 2 diabetes (15, 46–50). 
Previous studies have also implicated a relationship between 
ANGPTL3  levels  and  risk  of  type  2  diabetes  (15,  46). 
ANGPTL3 deficiency enhances insulin sensitivity in mice and 
humans (15, 22, 51), while loss-of-function ANGPTL4 gene 
variants are associated with improved glucose homeostasis 






and **P < 0.01. The data  shown  in panel B were published  in 
Bremer et al. (29).
Fig. 3.  Low plasma ANGPTL3 concentrations correlate with high 
plasma  adropin  concentrations  in  situations  of  fructose-induced 
metabolic  dysregulation.  The  data  shown  as  bar  graphs  are  esti-
mated marginal means for fasting plasma adropin concentrations at 
baseline  and  after  1  and  3 months  of  fructose.  Individual  unad-
justed data points are also shown (gray circles). The animals were 
separated  in  tertiles ranked  low to high by baseline plasma ANG-
PTL3 concentrations. There was a significant effect of tertile at the 
3-month time point (P = 0.001); animals with low plasma ANGPTL3 
concentrations had significantly higher plasma adropin concentra-
tions. **P < 0.005 and ***P = 0.001 compared with the 1st tertile.
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of  circulating CRP  or  IL-6  levels  in  response  to  fructose 
consumption are not affected by fish oil  supplementa-




The  RNAi  construct  targeting  ANGPTL3  synthesis  is 
highly effective in decreasing ANGPTL3 expression, as re-
flected by the marked decrease of plasma ANGPTL3 as well 
as  lowering  circulating  levels  of most  lipids/lipoproteins 
that  we  measured  (plasma  TGs,  VLDL-C,  APOC3,  and 
APOE) that are  implicated as risk factors for CVD in hu-
mans. Plasma HDL-C concentrations were also lowered by 








gests  circulating  ANGPTL3  levels  are  not  regulated  by 
pathways  involving  APOC3.  The  strong  correlations  ob-
served between plasma APOC3 and ANGPTL3 concentra-
tions  are primarily driven by  actions of  the  latter on  the 
clearance of lipoproteins from the circulation.
CONCLUSIONS
Increased  circulating  ANGPTL3  concentrations  in  re-
sponse to fructose consumption may be best explained by 
the development of fasting hyperinsulinemia and increases 
in  HOMA-IR,  which  are  indicators  of  insulin  resistance. 
Fig. 6.  Fasting  plasma  concentrations  of  APOA1 
(A), APOB (B), APOC3 (C), and APOE (D) before 
and  after  treating  rhesus macaques  with  an  RNAi 
construct targeting hepatic ANGPTL3 expression. 
Refer  to  the Fig. 4  legend for a description of  the 
study.
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tose  and n-3  fatty  acids) on ANGPTL3 and  suggests  that 








physiology,  role  of  genetics,  consequences,  and  treatment.  In 
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